K Weller1, N Schoepke, K Krause, E Ardelean, M Bräutigam, M Maurer. 1. Department of Dermatology and Allergy, Charité- Universitätsmedizin Berlin, Berlin, Germany Clinical Development, Novartis Pharma, Nürnberg, Germany.
Abstract
BACKGROUND: Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. OBJECTIVE: To analyse the management of urticaria patients in tertiary referral centres. METHODS: During a standardized expert-to-expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticaria patient care with a special focus on csU. RESULTS: On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non-sedating H(1)-antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine-resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow-up visits was reported to be above average in case of csU. CONCLUSION: This study indicates that some urticaria patients, especially those with unknown causes or with an H(1)-antihistamine-resistant disease, may benefit from a referral to tertiary care centres.
BACKGROUND:Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. OBJECTIVE: To analyse the management of urticariapatients in tertiary referral centres. METHODS: During a standardized expert-to-expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticariapatient care with a special focus on csU. RESULTS: On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non-sedating H(1)-antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine-resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow-up visits was reported to be above average in case of csU. CONCLUSION: This study indicates that some urticariapatients, especially those with unknown causes or with an H(1)-antihistamine-resistant disease, may benefit from a referral to tertiary care centres.
Authors: Mati Chuamanochan; Karsten Weller; Eugen Feist; Tilmann Kallinich; Marcus Maurer; Jasmin Kümmerle-Deschner; Karoline Krause Journal: World Allergy Organ J Date: 2019-03-14 Impact factor: 4.084
Authors: H Lapeere; M Baeck; A Stockman; V Sabato; M Grosber; M Moutschen; J Lambert; L Vandebuerie; L de Montjoye; H Rabijns; K Allewaert; R Schrijvers Journal: J Eur Acad Dermatol Venereol Date: 2019-08-19 Impact factor: 6.166
Authors: Karsten Weller; Marcus Maurer; Clive Grattan; Alla Nakonechna; Mohamed Abuzakouk; Frédéric Bérard; Gordon Sussman; Ana M Giménez-Arnau; Javier Ortiz de Frutos; André Knulst; G Walter Canonica; Kelly Hollis; Doreen McBride; Maria-Magdalena Balp Journal: Clin Transl Allergy Date: 2015-08-17 Impact factor: 5.871